Strides Pharma Science Limited has announced the incorporation of a new step-down wholly owned subsidiary named Pivot Path Private Limited through its subsidiary Arco Lab Private Limited. The new entity, incorporated on April 10, 2025, is set to focus on life sciences and manufacturing solutions, leveraging domain expertise and advanced digital technologies.
Pivot Path has been established with an authorised share capital of ₹10 lakh and an initial subscribed capital of ₹1 lakh. The subsidiary will provide outsourcing and business support services, with a strong emphasis on the pharmaceutical sector, both in India and globally.
According to the regulatory filing made by Strides Pharma, this incorporation is in line with a proposed Scheme of Arrangement previously communicated in March 2025. Under this scheme, Arco Lab intends to transfer its Life Sciences and Digital Innovation Capabilities to Pivot Path, enabling sharper focus and operational synergy in these segments.
While Pivot Path is yet to commence operations, the company aims to create impactful technological and domain-specific solutions in the healthcare ecosystem. Strides Pharma has confirmed that all required disclosures under SEBI regulations have been made and no government approvals were necessary for this internal restructuring.
